Korro Bio (KRRO) Stock Crashes as Novo Nordisk Pauses Pact, KRRO‑110 Disappoints and 34% Layoffs Extend Cash Runway – What Investors Need to Know Today
Korro Bio, Inc. (NASDAQ: KRRO) is at the center of one of biotech’s biggest shake‑ups of 2025. After releasing mixed early data from its lead RNA‑editing program, KRRO‑110, the company has announced deep layoffs, a strategic pivot in its pipeline and a 12‑month pause in its high‑profile collaboration with Novo Nordisk. The stock has responded with a brutal collapse. As of Thursday, 13 November 2025, here’s a full rundown of everything that has hit the tape around Korro Bio today and what it could mean for KRRO shareholders. KRRO stock: from low‑30s to single digits in a day Korro Bio